Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN-4: Eloralintide for osteoarthritis knee pain in adults with overweight or obesity
2025-523768-19-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in osteoarthritis (OA), obesity and Overweight comparing Eloralintide with Placebo (2 arms). Primary endpoints: Percent change from baseline in body weight and Change from baseline in WOMAC Pain Subscale Score. Planned start Apr 2026; status: authorised.
02
Drugs
eloralintide
03
Conditions
osteoarthritis (OA)obesityOverweight
Beyond the preview
Go deeper on 2025-523768-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523768-19-00.